PTIP associates with Artemis to dictate DNA repair pathway choice

PARP inhibitors (PARPis) are being used in patients with BRCA1/2 mutations. However, doubly deficient BRCA1(−/−)53BP1(−/−) cells or tumors become resistant to PARPis. Since 53BP1 or its known downstream effectors, PTIP and RIF1 (RAP1-interacting factor 1 homolog), lack enzymatic activities directly...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jiadong, Aroumougame, Asaithamby, Lobrich, Markus, Li, Yujing, Chen, David, Chen, Junjie, Gong, Zihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory Press 2014
Materias:
Research Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265673/
https://www.ncbi.nlm.nih.gov/pubmed/25512557
http://dx.doi.org/10.1101/gad.252478.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265673/
https://www.ncbi.nlm.nih.gov/pubmed/25512557
http://dx.doi.org/10.1101/gad.252478.114

Ejemplares similares